UnicoCell Biomed Co., Ltd. signed a cooperation agreement with Japan's New Cell Bio (NCB) to jointly enter the South Korean’s regenerative medicine market, focusing on stem cell and exosome products.
NCB is a Tokyo-based stem cell biotechnology company with operations in Busan, South Korea. NCB focuses on regenerative medicine, collaborates with Korea University Medical Center, and holds recognition from the Japanese Association for Regenerative Medicine. These credentials make NCB an ideal partner for UnicoCell's expansion into the Korean market. UnicoCell specializes in allogeneic stem cell regenerative medicine. Its investigational product ELIXCYTE®, for the treatments of knee osteoarthritis and chronic kidney disease, is currently advancing through clinical trials ahead of domestic competitors. The company operates Taiwan's only allogeneic cell bank with US FDA Master File acknowledgement and maintains a PIC/S GMP-certified pilot facility. UnicoCell offers customized CDMO services using proprietary cell therapy production technology.
In the exosome field, UnicoCell has also demonstrated outstanding performance. Its high-concentration stem cell-derived exosome products have been exported to Japan since 2018. Domestically, the company has formed a strategic alliance with Mentor Group, Taiwan’s largest hair salon chain, to enter the hair care market.
Korea's stem cell and exosome industry shows strong growth. This partnership leverages NCB's local expertise and medical networks to introduce UnicoCell's products into the Korean market, marking a significant milestone in UnicoCell's international expansion.
President Tsai of UnicoCell (right) and President Chang of NCB (left) jointly signed a cooperation agreement to enter the South Korean regenerative medicine market.
Contact: Ray Liu
Phone: 886-2-27922699
Mail: info@unicocell.com